GlobeNewswire 30/05 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 22/05 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 21/05 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 16/05 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 15/05 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 02/05 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 25/04 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 24/04 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 23/04 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 02/04 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 06/03 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 04/03 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 23/02 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 13/02 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 12/02 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
TeleTrader 12/02 Earnings preview: Robinhood, Coinbase and more
GlobeNewswire 08/02 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire 04/01 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer
GlobeNewswire 19/12/2023 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire 15/12/2023 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire 14/12/2023 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...
TeleTrader 08/11/2023 Biogen's Q3 revenue up 3% to $2.5B
GlobeNewswire 06/11/2023 Biogen Appoints Monish Patolawala to its Board of Directors
GlobeNewswire 25/10/2023 Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire 25/10/2023 New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise f...